Compare Incyte Corporation (INCY) vs Shopify Inc. (SHOP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Shopify Inc. — how do they compare? Incyte Corporation trades at $117.86 (market cap $23.11B), while Shopify Inc. trades at $123.28 (market cap $161.53B). The key difference: Shopify Inc. is far larger — about 7× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Shopify Inc. nearer its low. Which is the better fit depends on your goals.
| INCY | SHOP | |
|---|---|---|
Market Cap | $23.11B | $161.53B |
Sector | Health | Technology |
52-Week High | $118.52 | $179.01 |
52-Week Low | $67.38 | $95.40 |
Enterprise Value | $19.13B | $155.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SHOP trades at $125.88, up 1.88% today, with a bullish technical signal from moving averages. The stock shows strong revenue growth, reaching $11.56 billion in 2025, and has turned profitable with a net income margin of 10.77%. Recent news highlights its AI strategy and a Jefferies upgrade to Buy with a $160 target. Cash flow from operations improved to $2.03 billion, though valuation ratios remain elevated.
The outlook is positive, supported by analyst consensus and growth in AI-driven commerce. However, high P/E of 121.14 and competitive pressures from Amazon pose risks. Upside to the $150.08 consensus target depends on execution of AI initiatives and sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →
